Eagle Pharmaceuticals,Inc. (TLV:TEVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Eagle Pharmaceuticals,Inc. (TLV:TEVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of President and Chief Commercial Officer; Resignation of Director; Resignation of President

On January 2, 2017, in connection with his appointment as President and Chief Commercial Officer of Eagle Pharmaceuticals, Inc., or the Company, David Pernock resigned from the board of directors of the Company, or the Board, (including his position as a member of the Board’s Nominating and Corporate Governance Committee). In addition, in connection with Mr. Pernock’s appointment, Scott Tarriff resigned from his position as President of the Company, effective January 2, 2017. Mr. Tarriff will continue to serve as the Company’s Chief Executive Officer and as a member of the Board.

A description of the terms of Mr. Pernock’s employment with the Company, as well as a copy of Mr. Pernock’s employment offer letter, were included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2016.



About Eagle Pharmaceuticals, Inc. (TLV:TEVA)

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Eagle Pharmaceuticals, Inc. (TLV:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (TLV:TEVA) closed its last trading session down -790.00 at 13,600.00 with 628,899 shares trading hands.